Transcatheter embolization therapy in liver cancer: an update of clinical evidences.

摘要: Transarterial chemoembolization (TACE) is a form of intra-arterial catheter-based chemotherapy that selectively delivers high doses cytotoxic drug to the tumor bed combining with effect ischemic necrosis induced by arterial embolization. Chemoembolization and radioembolization are at core treatment liver hepatocellular carcinoma (HCC) patients who cannot receive potentially curative therapies such as transplantation, resection or percutaneous ablation. TACE for cancer has been proven be useful in local control, prevent progression, prolong patients’ life control patient symptoms. Recent evidence showed single-nodule HCC 3 cm smaller without vascular invasion, 5-year overall survival (OS) was similar hepatic radiofrequency Although being used decades, Lipiodol ® (Lipiodol Ultra Fluid , Guerbet, France) remains important tumor-seeking radio-opaque delivery vector interventional oncology. There have efforts improve chemotherapeutic agents tumors. Drug-eluting bead (DEB) relatively novel embolization system which allows fixed dosing ability release anticancer sustained manner. Three DEBs available, i.e., Tandem (CeloNova Biosciences Inc., USA), DC-Beads (BTG, UK) HepaSphere (BioSphere Medical, USA). (TARE) technique developed, efficient safe advanced cancers those complications. Two types microspheres available SIR-Spheres (Sirtex Medical Limited, Australia) TheraSphere UK). This review describes basic procedure TACE, properties efficacy some systems commercially and/or currently under clinical evaluation. The key trials transcatheter therapy summarized.